U.S. Markets closed

If You Had Bought Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Shares Three Years Ago You'd Have Made 231%

Simply Wall St

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. To wit, the Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) share price has flown 231% in the last three years. Most would be happy with that. And in the last month, the share price has gained 1.9%. This could be related to the recent financial results that were recently released - you could check the most recent data by reading our company report.

Check out our latest analysis for Corbus Pharmaceuticals Holdings

Given that Corbus Pharmaceuticals Holdings didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last 3 years Corbus Pharmaceuticals Holdings saw its revenue grow at 39% per year. That's well above most pre-profit companies. Meanwhile, the share price performance has been pretty solid at 49% compound over three years. This suggests the market has recognized the progress the business has made, at least to a significant degree. That's not to say we think the share price is too high. In fact, it might be worth keeping an eye on this one.

Depicted in the graphic below, you'll see revenue and earnings over time. If you want more detail, you can click on the chart itself.

NasdaqGM:CRBP Income Statement, April 5th 2019

It's good to see that there was some significant insider buying in the last three months. That's a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. You can see what analysts are predicting for Corbus Pharmaceuticals Holdings in this interactive graph of future profit estimates.

A Different Perspective

It's nice to see that Corbus Pharmaceuticals Holdings shareholders have gained 25% (in total) over the last year. But the three year TSR of 49% per year is even better. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.